Navigation Links
China Pharma Holdings, Inc. Reports Third Quarter 2010 Financial Results

HAIKOU CITY, China, Nov. 11, 2010 /PRNewswire-Asia-FirstCall/ -- China Pharma Holdings, Inc. (NYSE Amex: CPHI) ("China Pharma" or the "Company"), a leading fully-integrated specialty pharmaceuticals company in China, today announced financial results for the third quarter ended September 30, 2010.

ThirdQuarter Highlights

  • Revenue increased 20% to $18.7 million from $15.5 million in the third quarter of fiscal year 2009
  • Excluding an adjustment for a one-time non-cash change in bad debt estimate in third quarter 2009, net income increased 29% from $4.3 million in the year ago period to $5.5 million this quarter
  • Company completed phase I clinic trials for novel cephalosporin-based combination antibiotic

  • "Our well-balanced pharmaceutical portfolio continues to demonstrate healthy organic growth this quarter, led by Digestive Diseases and Other products. In particular, incremental sales of Omeprazole favorably impacted Digestive Diseases, while Granistron and Vitamin B6 drove Other product revenues during the reporting period," said China Pharma's President and CEO, Ms. Zhilin Li. "We also are very pleased with the successful completion of Phase I clinical trials of our novel cephalosporin-based combination antibiotic during third quarter 2010. Exciting new drugs such as this, along with other first-to-market generic medicines will enhance China Pharma's strong growth and profitability."

    Third Quarter ResultsThird quarter 2010 total revenues grew 20% to $18.7 million from $15.5 million in third quarter 2009. Digestive Diseases product sales for the third quarter 2010 grew by 51% year-over-year to $2.4 million, primarily due to continued strong sales of Omeprazole, the Company's generic gastroesophageal reflux disease (GERD) drug launched in fourth quarter 2009.  In the third quarter of 2010, the Company's Other Products category rose 100% year-over-year to $4.5 million, primarily due to higher sales of Granistron and Vitamin B6, the latter of which is one of two China Pharma products on the National EDL (Essential Drug List).  Sales from the Company's Central Nervous System (CNS), Cerebral and Cardio Vascular products experienced modest growth of 5% to $5.9 million from $5.6 million in the comparable 2009 period due to strong performances from Ozagrel and Gastrodin Injection. Sales from the Company's Anti-Viro/Infection and Respiratory products decreased by 2% to $6.0 million from $6.1 million in the same quarter last year, but this group continues to be the largest contributor to overall Company revenue.

    Gross profit for the three months ended September 30, 2010 increased by 16.5% to $7.6 million from $6.5 million in the comparable period last year. Gross margin for the third quarter was 40.8% as compared to 42.2% in the previous year quarter. The decrease in gross margin was largely due to increased sales volume from lower margin products compared to the same period a year ago.  

    Total operating expenses were $1.4 million (7.7% of revenue) for the three months ended September 30, 2010, compared to credit balance of $1.5 million in the same period last year, which included a one-time non-cash benefit of $2.8 million for bad debt estimate change.

    Net income was $5.5 million, or $0.13 per basic and diluted share, compared to $7.2 million, or $0.17 per basic and diluted share in the year ago period,  excluding the effect of change in bad debt estimate in the third quarter 2009, net income increased 29% from $4.3 million in the year ago period to $5.5 million this quarter  

    Nine Months ResultsRevenues for the nine months ended September 30, 2010 were $50.4 million, up 20% from revenues of $42.1 million for the nine months ended September 30, 2009. Gross profit for the nine months ended September 30, 2010 was $20.8 million, up 13% from gross profit of $18.4 million for the corresponding period of 2009. Gross margin was 41.3%, compared to 43.7% for the first nine months of 2009. Income from operations was $17.0 million, up 0.4% from $16.9 million for the first nine months of 2009.

    Net income was $15.1 million, or $0.35 per basic and diluted share, compared to $15.1 million, or $0.36 per basic and diluted share in the year ago period, which included a one-time, non-cash benefit of $2.8 million from a change in bad debt estimate.  Excluding the adjustment for bad debt estimate in the first nine months of 2009, net income increased 20% from $12.6 million in the year ago period to $15.1 million during the first nine months of 2010.

    Financial ConditionAs of September 30, 2010, the Company had cash and cash equivalents of $4.6 million compared to $3.6 million as of December 31, 2009. Year-over-year, working capital increased to $74 million from $61 million and the current ratio rose to 7.7 times from 6.8 times.

    Accounts receivable balance net of bad debt allowance rose to $56.8 million at September 30, 2010 from $51.2 million at the end of 2009. The Company's management team continues to be sharply focused on improving accounts receivable collection and expects to make further progress in the quarters to come.

    For the nine months ended September 30, 2010, cash flow from operating activities was $6.1 million, as compared to $6.4 million during the same period in 2009.  

    Financial GuidanceGiven China Pharma's solid performance during the first nine months of 2010 and the outlook for the remainder of the year, the Company reaffirms its previous guidance of revenue growth of between 20% and 25% in 2010.

    "Looking into 2011, we are optimistic that our promising later stage pipeline products will begin to contribute to China Pharma's overall performance.  In the meantime, we remain focused on managing our current portfolio for growth and profitability, while positioning China Pharma to benefit from China's unprecedented $124 billion healthcare reform program," said Ms. Li.  "We believe our future success will be defined by our high-quality manufacturing facilities, strong distribution relationships, and commercialization expertise."

    Pipeline UpdateAs of September 30, 2010, China Pharma had nine pipeline drugs in different stages of registration process, including three that have passed China State Food and Drug Administration ("SFDA") technical analysis and entered clinical trials.

  • The Company has completed clinical trials of Candesartan, a front-line drug therapy for the treatment of hypertension. The Company has completed all testing procedures and currently awaits final SFDA production approval.
  • The Company continues to receive positive feedback from patients in the clinical trial of Rosuvastatin, a generic form of Crestor. The majority of patients in the clinical trial have completed the treatment cycle and the trial is near completion.
  • The Company completed Phase I clinical trials of its novel cephalosporin-based combination antibiotic in the third quarter of 2010.  Phase I of the clinical trials focused on the study of clinical pharmacology as well as the evaluation of safety on the human body, while observing tolerance and pharmacokinetics to provide support for dosage and drug delivery design. Phase II has commenced.

  • Conference CallThe Company will hold a conference call at 8:00 am EST on November 11, 2010 to discuss third quarter 2010 results.  Listeners may access the call by dialing 1-800-659-2056 or 1-617-614-2714 for international callers; access code: 56441223.  A webcast will also be available through CPHI's website at  A replay of the call will be accessible through November 18, 2010 by dialing 1-888-286-8010 or 1-617-801-6888 for international callers; access code: 99472174.

    Use of Non GAAP Financial MeasuresGAAP results for the three and nine month periods ended September 30, 2009 include non-recurring benefit from change of bad debt estimate. To supplement its consolidated financial statements presented on a GAAP basis, the Company has provided non-GAAP adjusted financial information, which are adjusted net income and adjusted diluted earnings per share, excluding the impact of these items. The Company's management believes that this adjusted measure provides investors with a better understanding of how the results relate to the Company's historical performance. A reconciliation of adjustment to GAAP results appears in the tables accompanying this press release. This additional adjusted information is not meant to be considered in isolation or as a substitute for GAAP financials. The adjusted financial information that the Company provides also may differ from the adjusted information provided by other companies.

    About China Pharma Holdings, Inc.China Pharma Holdings, Inc. is a rapidly growing specialty pharmaceutical company that develops, manufactures and markets a diversified portfolio of products focused on conditions with a high incidence and high mortality rates in China, including cardiovascular, CNS, infectious, and digestive diseases. The Company's cost-effective, high-margin business model is driven by market demand and supported by eight scalable GMP-certified product lines covering the major dosage forms. In addition, the Company has a broad and expanding nationwide distribution network across all major cities and provinces in China. The Company's wholly-owned subsidiary, Hainan Helpson Medical & Biotechnology Co., Ltd., is located in Haikou City, Hainan Province. For more information about China Pharma Holdings, Inc., please visit

    Safe Harbor Statement  Certain statements in this press release constitute forward-looking statements for purposes of the safe harbor provisions under The Private Securities Litigation Reform Act of 1995. Any statements set forth above that are not historical facts are forward-looking statements that involve risks and uncertainties that could cause actual results to differ materially from those in the forward-looking statements, which may include, but are not limited to, such factors as the achievability of financial guidance, success of new product development, unanticipated changes in product demand, increased competition, downturns in the Chinese economy, uncompetitive levels of research and development, and other information detailed from time to time in the Company's filings and future filings with the United States Securities and Exchange Commission. The forward-looking statements made herein speak only as of the date of this press release and the Company undertakes no duty to update any forward-looking statement to conform the statement to actual results or changes in the Company's expectations except as required by applicable law or regulation.

    3,634,753Trade accounts receivable, less allowance for doubtfulaccounts of $2,976,077 and $2,718,358, respectively56,792,74251,238,339Other receivables, less allowance for doubtfulaccounts of $21,880 and $3,556, respectively132,28078,525Advances to suppliers3,358,1131,798,446Inventory19,861,05714,233,073Deferred tax assets523,840319,820Total Current Assets85,229,46471,302,956Advances for purchases of property and equipment and intangible assets3,574,4963,599,949Property and equipment, net of accumulated depreciation of$2,661,208 and $2,020,462, respectively6,394,5386,705,873Intangible assets, net of accumulated amortization of$2,082,188 and $1,359,048, respectively26,342,40619,332,284TOTAL ASSETS$   121,540,904$ 100,941,062LIABILITIES AND STOCKHOLDERS' EQUITYCurrent Liabilities:Trade accounts payable$
    3,957,923Accrued expenses55,04347,435Accrued taxes payable2,180,8511,528,691Other payables75,56058,191Advances from customers1,030,7661,037,693Other payables - related parties303,64475,741Short-term notes payable2,985,9213,802,726Total Current Liabilities11,032,11710,508,400Long-term research and development commitments-36,565Total Liabilities11,032,11710,544,965Stockholders' Equity:Preferred stock, $0.001 par value; 5,000,000 shares authorized;no shares issued or outstanding--Common stock, $0.001 par value; 95,000,000 sharesauthorized; 43,393,642 shares and 42,308,350 sharesoutstanding, respectively43,39342,308Additional paid-in capital24,041,61621,178,114Retained earnings78,328,69863,272,868Accumulated foreign currency translation adjustment8,095,0805,902,807Total Stockholders' Equity110,508,78790,396,097TOTAL LIABILITIES AND STOCKHOLDERS' EQUITY$   121,540,904$ 100,941,062CHINA PHARMA HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF OPERATIONSAND COMPREHENSIVE INCOME(Unaudited)For the Three Months EndedFor the Nine Months EndedSeptember 30,September 30,2010200920102009Revenue$ 18,680,390$ 15,522,953$ 50,414,254$ 42,116,290Cost of revenue11,055,2548,979,08329,610,97323,724,155Gross profit7,625,1366,543,87020,803,28118,392,135Operating expenses:Selling expenses449,295807,2311,653,7632,013,915General and administrative expenses873,157521,6762,420,4121,563,330Bad debt expense (benefit)107,186(2,836,495)215,707(2,101,710)Total operating expenses1,429,638(1,507,588)4,289,8821,475,535Government subsidy income--465,663-Income from operations6,195,4988,051,45816,979,06216,916,600Other income (expense):Interest income1,1473,95613,30525,265Interest expense(37,667)(24,436)(139,788)(103,143)Net other income (expense)(36,520)(20,480)(126,483)(77,878)Income before income taxes6,158,9788,030,97816,852,57916,838,722Income tax expense(674,051)(867,750)(1,796,749)(1,711,703)Net income5,484,9277,163,22815,055,83015,127,019Other comprehensive income - foreign currencytranslation adjustment1,774,57585,8962,192,273179,085Comprehensive income$   7,259,502$   7,249,124$ 17,248,103$ 15,306,104Earnings per Share:Basic$
    .36CHINA PHARMA HOLDINGS, INC.CONDENSED CONSOLIDATED STATEMENTS OF CASH FLOWS(Unaudited)For the Nine Months EndedSeptember 30,20102009Cash Flows from Operating Activities:Net income$   15,055,830$   15,127,019Depreciation and amortization1,271,251986,310Stock based compensation281,587-Bad debt expense (benefit)215,707(2,101,710)Deferred tax assets(193,953)210,171Changes in assets and liabilities:Trade accounts receivable(4,610,175)(10,841,625)Other receivables(69,154)82,949Advances to suppliers(1,495,898)1,170,103Inventory(5,239,859)(1,742,681)Trade accounts payable277,2752,772,775Accrued expenses(30,168)(11,339)Accrued taxes payable609,646393,724Other payables15,972233,155Advances from customers(27,982)109,238Net Cash Provided by Operating Activities6,060,0796,388,089Cash Flows from Investing Activities:Advances for purchases of property and equipment and intangible assets(1,615,399)(2,921,715)Purchase of property and equipment(219,904)(255,273)Purchase of intangible assets(5,311,961)(7,621,781)Net Cash Used in Investing Activities(7,147,264)(10,798,769)Cash Flows from Financing Activity:Proceeds from issuance of notes payable2,934,1003,799,775Payments of notes payable(3,814,330)(2,484,468)Borrowing from a related party227,903-Proceeds from exercise of warrants2,583,000-Net Cash Provided by Financing Activity1,930,6731,315,307Effect of Exchange Rate Changes on Cash83,19113,001Net Increase (Decrease) in Cash926,679(3,082,372)Cash and Cash Equivalents at Beginning of Period3,634,7536,927,149Cash and Cash Equivalents at End of Period$
    3,844,777Supplemental Cash Flow Information:Cash paid for interest$
    3,143Cash paid for income taxes1,889,8101,413,306(Unaudited, $ in thousand except share and per share data)For the Three Months Ended September 30,For the Nine Months Ended September 30,2010200920102009Net




    EPSAdjusted net income, excludingapproximate after-tax impact of one‐time bad debt





    $0.30estimate change (Non‐GAAP)Approximate after-tax impact of one-time bad debt estimate change (a)





    $0.06Net income as reported (GAAP)





    $0.36Diluted weighted average sharesoutstanding

    43,407,17542,278,93843,503,33042,278,938(a) Represents the approximate amount that net income or EPS of the corresponding periods would have decreased by if bad debt estimate had been changed prior to the beginning of 2009.Contact:China Pharma Holdings, Inc.Phone: +86-898-6681-1730 (China)Email: hps@chinapharmaholdings.comCCG Investor RelationsKalle Ahl, CFA, Account ManagerPhone: +1-646-833-3417 (New York)Email: kalle.ahl@ccgir.comVivian Chen, Sr. Market Intelligence Exec.Phone: +1-646-701-7445(New York)Email:

    SOURCE China Pharma Holdings, Inc.
    Copyright©2010 PR Newswire.
    All rights reserved

    Related medicine technology :

    1. HUYA Bioscience Intl Announces Clinical Trial Milestones in China for Promising New Anti-Arrhythmic Compound; Data Supports Desirable Safety Profile
    2. HUYA Bioscience Intl Announces World-Class Clinical Advisory Team for New Anti-Arrhythmic Compound Sourced From China
    3. HUYA Bioscience Intl Announces First Pre-IND Outcome for a Development Stage Compound Sourced From China - HBI-8000, Promising New Cancer Compound
    4. HUYA Bioscience Intl Announces Pre-IND Outcome for HBI-3000 - Promising Anti-Arrhythmia Compound Sourced From China
    5. China Sky One Medical, Inc. Announces 26 New Drugs in Clinical Trials
    6. RHEI Pharmaceuticals Announces the Initiation of the Final Clinical Study for Approval of Tibozole in China
    7. Varian Medical Systems to Exhibit Cancer Treatment and X-ray Imaging Technologies at China Med Exhibition
    8. China Sky One Medical, Inc. Achieves Significant Breakthrough in Research for Sudden Cardiac Death (SCD) Early Examination Kit
    9. China Animal Welfare Law Under Review While 36,000 Dogs Culled
    10. China-Biotics, Inc. Prices $69 Million Public Offering of Common Stock
    11. Clifford Chance Advises Pfizer on Conditional Clearance in China of Its Merger with Wyeth
    Post Your Comments:
    (Date:10/4/2017)... SEOUL, South Korea , Oct. 4, 2017 /PRNewswire/ ... launched its next-generation CPR training aide "cprCUBE" on Kickstarter. ... of chest compression during cardiac arrests with better efficiency ... patient-mannequins. It also offers real-time feedback on efficacy of ... The crowdfunding campaign has a goal to raise ...
    (Date:10/2/2017)... , Oct. 2, 2017  Eli Lilly and Company ... results for the third quarter of 2017 on Tuesday, ... call on that day with the investment community and ... The conference call will begin at 9 a.m. ... access a live webcast of the conference call through ...
    (Date:9/28/2017)... Sept. 28, 2017 Hill-Rom Holdings, Inc. (NYSE: ... conference call and webcast on Friday, November 3, 2017, ... and ending at approximately 8:30 a.m. (CDT) / 9:30 ... company,s 2017 financial performance and guidance for 2018, Hill-Rom ... to enhance operational performance, and long-range financial outlook through ...
    Breaking Medicine Technology:
    (Date:10/13/2017)... ... October 13, 2017 , ... As health professionals work to ... “patient engagement.” The patient is doing more than filling out a survey; in many ... is an increasing emphasis in health care and research on the importance of active ...
    (Date:10/13/2017)... ... , ... The American Board of Family Medicine's (ABFM) Board of Directors has ... succeeding Dr. James C. Puffer upon his retirement. Dr. Newton will serve in the ... at the end of 2018. Upon assuming the role of President and CEO on ...
    (Date:10/13/2017)... Vegas, Nevada (PRWEB) , ... October 13, 2017 , ... ... 7® Hemp CBD Oil utilizing Purzorb™ technology. Applying the Purzorb™process to full spectrum CBD ... dose required and providing a CBD form that can be easily incorporated into liquid ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Lori R. Somekh, founder of the ... national organization of elder law and special needs planning attorneys. “Membership in ElderCounsel helps ... provides a forum to network with elder law attorneys nationwide,” said Somekh. , ...
    (Date:10/13/2017)... ... October 13, 2017 , ... Many families have long-term insurance that covers ... companies have a waiver for care if the client has a cognitive impairment diagnosis. ... pays for care, is often waived, so the benefits from their insurance start immediately,” ...
    Breaking Medicine News(10 mins):